- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07940205
Machine-learning Algorithm for Prediction of CKD From Retinal Images (healthy route)
A Validation Study to Assess Performance Accuracy of a Machine-Learning Algorithm for the Prediction of Chronic Kidney Disease (CKD) From Digital Retinal Images
This is a non-interventional study being conducted to validate the performance of a machine learning algorithm for prediction of eGFR from digital retinal images in a target population for future intended use as a populated-based screening tool. Secondary objectives will include prediction of blood pressure (> or ≤ 140/90 mmHg) and presence or absence of T2DM as determined by glycated haemoglobin (HbA1c >6.5%) or on the basis of clinical history. Once validated, the methodology will be deployed for health screening to improve access to healthcare.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Mohamed Khalis, Professor
- Telefoonnummer: +212 628-245023
- E-mail: mkhalis@um6ss.ma
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
The study population consists of adult patients diagnosed with chronic kidney disease (CKD), hypertension, diabetes mellitus, or without these conditions, attending routine outpatient clinics at Hôpital Universitaire International Cheikh Khalifa Ibn Zaid in Casablanca and Centre Hospitalier Universitaire Hassan II in Fez, Morocco.
Beschrijving
Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
- Participant must be ≥ 18 years of age, at the time of signing the informed consent.
- Previously documented eGFR ≥ 3months
- Any participant with a positive dipstick result for proteinuria of at least trace
- Capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol
Exclusion Criteria:
-
Participants are excluded from the study if any of the following criteria apply:
- As judged by the investigator, any evidence of a condition which in the investigator's opinion makes it undesirable for the participant to participate in the study.
- Any known eye condition that may preclude clear imaging of the retina for example; cataracts
- Individuals with hypertensive emergencies and hyperglycemic or hypoglycemic emergencies
- Involvement in the planning and/or conduct of the study (applies to HHA/ AstraZeneca staff and/or staff at the study site).
- Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: CASE_CONTROL
- Tijdsperspectieven: CROSS_SECTIONAL
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
CKD Cases
350 participants (cases) with diabetes and/or hypertension and/or CKD with previously documented eGFR < 60 ml/min/1.73m2 ≥3 months |
A machine learning-based algorithm analyzes retinal images to assess its ability to detect chronic kidney disease |
|
Controls
150 (controls) with previously documented eGFR ≥ 60 ml/min/1.73m2 ≥ 3 months |
A machine learning-based algorithm analyzes retinal images to assess its ability to detect chronic kidney disease |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The accuracy of a machine-learning based algorithm to predict high risk CKD from digital retinal images
Tijdsspanne: Baseline
|
To quantify the discrimination of the machine-learning algorithm for identifying the binary target condition of persistent eGFR <60 mL/min/1.73 m², using standard-of-care serum creatinine as the reference standard and the AUROC with a 95% confidence interval as the primary performance measure |
Baseline
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Accuracy of the Machine Learning Algorithm for Detection of Hypertension and T2DM
Tijdsspanne: Baseline
|
To quantify the sensitivity, specificity, and discriminative performance of a machine-learning-based algorithm for identifying SBP >140 mmHg from digital retinal images, using standard-of-care assessment as the reference standard and the AUROC with a 95% confidence interval as the primary performance measure |
Baseline
|
Medewerkers en onderzoekers
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Endocriene systeemziekten
- Vaatziekten
- Hart-en vaatziekten
- Pathologische processen
- Mannelijke urogenitale ziekten
- Nier Ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Chronische ziekte
- Ziekte attributen
- Metabole ziekten
- Glucosemetabolismestoornissen
- Suikerziekte
- Nierinsufficiëntie
- Pathologische aandoeningen, tekenen en symptomen
- Voedings- en stofwisselingsziekten
- Hypertensie
- Diabetes mellitus, type 2
- Nierinsufficiëntie, chronisch
Andere studie-ID-nummers
- CKD-AI-2026-07
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .